Publications

@article{Mirzaev2024,

title = {Systematic review and meta-analysis of hepatitis E seroprevalence in Southeast Asia: a comprehensive assessment of epidemiological patterns},

author = {Ulugbek Khudayberdievich Mirzaev and Serge Ouoba and Ko Ko and Zayar Phyo and Chanroth Chhoung and Akuffo Golda Ataa and Aya Sugiyama and Tomoyuki Akita and Junko Tanaka},

url = {https://pubmed.ncbi.nlm.nih.gov/38789918/},

doi = {10.1186/S12879-024-09349-2},

issn = {1471-2334},

year  = {2024},

date = {2024-01-01},

journal = {BMC infectious diseases},

volume = {24},

issue = {1},

publisher = {BMC Infect Dis},

abstract = {The burden of hepatitis E in Southeast Asia is substantial, influenced by its distinct socio-economic and environmental factors, as well as variations in healthcare systems. The aim of this study was to assess the pooled seroprevalence of hepatitis E across countries within the Southeast Asian region by the UN division. The study analyzed 66 papers across PubMed, Web of Science, and Scopus databases, encompassing data from of 44,850 individuals focusing on anti-HEV seroprevalence. The investigation spanned nine countries, excluding Brunei and East Timor due to lack of data. The pooled prevalence of anti-HEV IgG was determined to be 21.03%, with the highest prevalence observed in Myanmar (33.46%) and the lowest in Malaysia (5.93%). IgM prevalence was highest in Indonesia (12.43%) and lowest in Malaysia (0.91%). The study stratified populations into high-risk (farm workers, chronic patients) and low-risk groups (general population, blood donors, pregnant women, hospital patients). It revealed a higher IgG\textemdash28.9%, IgM\textemdash4.42% prevalence in the former group, while the latter group exhibited figures of 17.86% and 3.15%, respectively, indicating occupational and health-related vulnerabilities to HEV. A temporal analysis (1987\textendash2023), indicated an upward trend in both IgG and IgM prevalence, suggesting an escalating HEV burden. These findings contribute to a better understanding of HEV seroprevalence in Southeast Asia, shedding light on important public health implications and suggesting directions for further research and intervention strategies. Key points Research Question Investigate the seroprevalence of hepatitis E virus (HEV) in Southeast Asian countries focusing on different patterns, timelines, and population cohorts. Findings Sporadic Transmission of IgG and IgM Prevalence: • Pooled anti-HEV IgG prevalence: 21.03% • Pooled anti-HEV IgM prevalence: 3.49% Seroprevalence among specific groups: High-risk group (farm workers and chronic patients): • anti-HEV IgG: 28.9% • anti-HEV IgM: 4.42% Low-risk group (general population, blood donors, pregnant women, hospital patients): • anti-HEV IgG: 17.86% • anti-HEV IgM: 3.15% Temporal Seroprevalence of HEV: Anti-HEV IgG prevalence increased over decades (1987\textendash1999; 2000\textendash2010; 2011\textendash2023): 12.47%, 18.43%, 29.17% as an anti-HEV IgM prevalence: 1.92%, 2.44%, 5.27% Importance Provides a comprehensive overview of HEV seroprevalence in Southeast Asia. Highlights variation in seroprevalence among different population groups. Reveals increasing trend in HEV seroprevalence over the years. Distinguishes between sporadic and epidemic cases for a better understanding of transmission dynamics.},

keywords = {Asia, doi:10.1186/s12879-024-09349-2, Female, Hepatitis Antibodies* / blood, Hepatitis E virus* / immunology, Hepatitis E* / blood, Hepatitis E* / epidemiology, Humans, Immunoglobulin G* / blood, Immunoglobulin M* / blood, Junko Tanaka, Male, MEDLINE, Meta-Analysis, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11127338, pmid:38789918, Pregnancy, Prevalence, PubMed Abstract, Risk Factors, Serge Ouoba, Seroepidemiologic Studies, Southeastern / epidemiology, Systematic review, Ulugbek Khudayberdievich Mirzaev},

pubstate = {published},

tppubtype = {article}

}

@article{Phyo2024,

title = {Intermediate hepatitis C virus (HCV) endemicity and its genotype distribution in Myanmar: A systematic review and meta-analysis},

author = {Zayar Phyo and Ko Ko and Serge Ouoba and Aya Sugiyama and Ulugbek Khudayberdievich Mirzaev and Golda Ataa Akuffo and Chanroth Chhoung and Tomoyuki Akita and Junko Tanaka},

url = {https://pubmed.ncbi.nlm.nih.gov/39298388/},

doi = {10.1371/JOURNAL.PONE.0307872},

issn = {1932-6203},

year  = {2024},

date = {2024-01-01},

journal = {PloS one},

volume = {19},

issue = {9},

publisher = {PLoS One},

abstract = {Background Comprehensive details on Hepatitis C virus (HCV) infection in Myanmar are lacking. This study determined the prevalence of HCV antibodies and ribonucleic acid (RNA) and the distribution of HCV genotypes across different populations in Myanmar from 1990 to 2023. Material and methods A systematic search in PubMed, Web of Science, Scopus, and local journals identified studies reporting on HCV antibodies, RNA, and genotypes, excluding clinical research related to liver disease prognosis. Screening and data extraction was done by two authors and study populations were categorized into low-risk, high-risk, liver disease patients, and refugees outside the country. The pooled prevalence was performed by Dersimonian and Laird method using the R program. The publication bias was shown by funnel plot, the Egger test was used to assess the symmetry of the plot, and the heterogeneity was examined by the Cochran Q test and I2 index. Results Out of 135 reports screened for eligibility, 35 reports comprising 51 studies were included in which 33 studies provided data on HCV seroprevalence in 685,403 individuals, 8 studies reported HCV RNA prevalence in 25,018 individuals, and 10 studies examined HCV genotypes in 1,845 individuals. The pooled seroprevalence of HCV among low-risk, high-risk, liver disease patients and refugees were 2.18%, 37.07%, 33.84%, and 2.52% respectively. HCV RNA-positive rates in these groups were 1.40%, 5.25%, 24.96%, and 0.84% respectively. Seroprevalence studies showed publication bias (Egger test},

keywords = {doi:10.1371/journal.pone.0307872, Endemic Diseases, Genotype*, Hepacivirus* / genetics, Hepacivirus* / isolation \& purification, Hepatitis C* / epidemiology, Hepatitis C* / virology, Humans, Junko Tanaka, Ko Ko, MEDLINE, Meta-Analysis, Myanmar / epidemiology, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC11412534, pmid:39298388, Prevalence, PubMed Abstract, RNA, Seroepidemiologic Studies, Systematic review, Viral / genetics, Zayar Phyo},

pubstate = {published},

tppubtype = {article}

}

@article{Ouedraogo2023,

title = {The burden of the coronavirus disease 2019 virus infection in Burkina Faso: Results from a World Health Organization UNITY population-based, age-stratified sero-epidemiological investigation},

author = {Samiratou Ouedraogo and Isidore Tiandiogo Traor\'{e} and Dramane Kania and Nongodo Firmin Kabor\'{e} and Ariane Mamguem Kamga and Hermann Badolo and Mimbour\'{e} Yara and Guillaume Sanou and Amariane Kon\'{e} and Samdapawind\'{e} Th\'{e}r\`{e}se Kagon\'{e} and Esperance Ou\'{e}draogo and Blahima Konat\'{e} and Rachel M\'{e}dah and Nathalie Rekeneire and Armel Poda and Arnaud Eric Diendere and Boukary Ou\'{e}draogo and Oumar Billa and Gilles Paradis and Halidou Tinto and Tienhan Sandrine Dabakuyo-Yonli},

url = {https://pubmed.ncbi.nlm.nih.gov/38019697/},

doi = {10.1111/IRV.13216},

issn = {1750-2659},

year  = {2023},

date = {2023-01-01},

journal = {Influenza and other respiratory viruses},

volume = {17},

issue = {11},

publisher = {Influenza Other Respir Viruses},

abstract = {Background: This study aimed to estimate the anti-SARS-CoV-2 antibody seroprevalence in the general population of Bobo-Dioulasso and Ouagadougou (Burkina Faso). Methods: We collected from March to April 2021 blood samples from randomly selected residents in both main cities based on the World Health Organization (WHO) sero-epidemiological investigations protocols and tested them with WANTAI SARS-CoV-2 total antibodies enzyme-linked immunosorbent assay (ELISA) kits intended for qualitative assessment. We also recorded participants' socio-demographic and clinical characteristics and information on exposure to SARS-CoV-2. Data were analysed with descriptive and comparative statistics. Results: We tested 5240 blood samples collected between 03 March and 16 April 2021. The overall test-adjusted seroprevalence for SARS-CoV-2 antibodies was (67.8% [95% CI 65.9\textendash70.2]) (N = 3553/3982). Seroprevalence was highest among participants aged 15\textendash18 years old (74.2% [95% CI 70.5\textendash77.5]) (N = 465/627), compared with those aged 10\textendash14 years old (62.6% [95% CI 58.7\textendash66.4]) (N = 395/631), or those over 18 (67.6% [95% CI 66.2\textendash69.1]) (N = 2693/3982). Approximately 71.0% (601/860) of participants aged 10\textendash18 years old who tested positive for SARS-CoV-2 antibodies experienced no clinical COVID-19 symptoms in the weeks before the survey, compared with 39.3% (1059/2693) among those aged over 18 years old. Conclusion: This study reports the results of the first known large serological survey in the general population of Burkina Faso. It shows high circulation of SARS-CoV-2 in the two cities and a high proportion of asymptomatic adolescents. Further studies are needed to identify the SARS-CoV-2 variants and to elucidate the factors protecting some infected individuals from developing clinical COVID-19.},

keywords = {Adolescent, Adult, Antibodies, Burkina Faso / epidemiology, Child, COVID-19* / epidemiology, doi:10.1111/irv.13216, Humans, Isidore Tiandiogo Traor\'{e}, MEDLINE, Middle Aged, National Center for Biotechnology Information, National Institutes of Health, National Library of Medicine, NCBI, NIH, NLM, PMC10655778, pmid:38019697, PubMed Abstract, Samiratou Ou\'{e}draogo, SARS-CoV-2*, Seroepidemiologic Studies, Surveys and Questionnaires, Tienhan Sandrine Dabakuyo-Yonli, Viral},

pubstate = {published},

tppubtype = {article}

}

@article{Ouoba2021-ug,

title = {Epidemiologic profile of hepatitis C virus infection and  genotype distribution in Burkina Faso: a systematic review with  meta-analysis},

author = {Serge Ouoba and Jean Claude Romaric Pingdwinde Ouedraogo and Moussa Lingani and Bunthen E and Md Razeen Ashraf Hussain and Ko Ko and Shintaro Nagashima and Aya Sugiyama and Tomoyuki Akita and Halidou Tinto and Junko Tanaka},

doi = {10.1186/s12879-021-06817-x},

issn = {1471-2334},

year  = {2021},

date = {2021-11-01},

urldate = {2021-11-01},

journal = {BMC Infect. Dis.},

volume = {21},

number = {1},

pages = {1126},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Detailed characteristics of Hepatitis C virus (HCV) 

 infection in Burkina Faso are scarce. The main aim of this study 

 was to assess HCV seroprevalence in various settings and 

 populations at risk in Burkina Faso between 1990 and 2020. 

 Secondary objectives included the prevalence of HCV Ribonucleic 

 acid (RNA) and the distribution of HCV genotypes. METHODS: A 

 systematic database search, supplemented by a manual search, was 

 conducted in PubMed, Web of Science, Scopus, and African Index 

 Medicus. Studies reporting HCV seroprevalence data in low and 

 high-risk populations in Burkina Faso were included, and a 

 random-effects meta-analysis was applied. Risk of bias was 

 assessed using the Joanna Briggs institute checklist. RESULTS: 

 Low-risk populations were examined in 31 studies involving a 

 total of 168,151 subjects, of whom 8330 were positive for HCV 

 antibodies. Six studies included a total of 1484 high-risk 

 persons, and 96 had antibodies to HCV. The pooled seroprevalence 

 in low-risk populations was 3.72% (95% CI: 3.20-4.28) and 

 4.75% (95% CI: 1.79-8.94) in high-risk groups. A 

 non-significant decreasing trend was observed over the study 

 period. Seven studies tested HCV RNA in a total of 4759 

 individuals at low risk for HCV infection, and 81 were positive. 

 The meta-analysis of HCV RNA yielded a pooled prevalence of 

 1.65% (95% CI: 0.74-2.89%) in low-risk populations, which is 

 assumed to be indicative of HCV prevalence in the general 

 population of Burkina Faso and suggests that about 301,174 

 people are active HCV carriers in the country. Genotypes 2 and 1 

 were the most frequent, with 60.3% and 25.0%, respectively. 

 CONCLUSIONS: HCV seroprevalence is intermediate in Burkina Faso 

 and indicates the need to implement effective control 

 strategies. There is a paucity of data at the national level and 

 for rural and high-risk populations. General population 

 screening and linkage to care are recommended, with special 

 attention to rural and high-risk populations.},

note = {© 2021. The Author(s).

PMID: 34724902 

PMCID: PMC8561994},

keywords = {Burkina Faso, Burkina Faso/epidemiology, Genotype, Hepacivirus/genetics, Hepatitis C, Hepatitis C/epidemiology, Humans, Prevalence, Seroepidemiologic Studies, Seroprevalence, Systematic review},

pubstate = {published},

tppubtype = {article}

}